Upadacitinib, an oral selective and reversible Janus kinase (JAK) inhibitor approved for atopic dermatitis (AD) in patients older than 12, has shown efficacy in psoriatic arthritis and plaque psoriasis in adults.1,2 Upadacitinib inhibits JAK phosphorylation and displays more selectivity toward JAK1 to reduce inflammation. This evidence concerns the gene JAK1 and Alzheimer disease.